The Motley Fool·Sep 3, 2026
Surgery Partners Director Teresa DeLuca Buys 11,250 SharesThe purchase was valued at approximately $161,000. DeLuca's total position now consists of 68,093 shares.
Surgery Partners' acquisition-driven growth is maturing, with revenue growth decelerating to 2.7% in 2026Q2 from 17.5% in 2024Q4, while gross margin contracted from 27.0% to 22.4% over the same period, indicating rising cost pressures. The company continues to...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | $0.10+72.6% vs $0.06 | $849M+2.3% vs $830M |
Q2 2026 May 5, 2026 | -$0.03+80.0% vs -$0.15 | $811M+1.7% vs $798M |
Q2 2026 Mar 2, 2026 | $0.12-61.3% vs $0.31 | $885M+2.1% vs $867M |
Q4 2025 Nov 10, 2025 | $0.13-31.6% vs $0.19 | $822M-5.2% vs $867M |
The purchase was valued at approximately $161,000. DeLuca's total position now consists of 68,093 shares.
BlackRock Inc. acquired a new position in shares of Surgery Partners, Inc. (NASDAQ: SGRY) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 6,241,503 shares of the company's stock, valued at approximately $104,857,000. BlackRock Inc. owned 4.77% of Surgery Partners at the
Weak July jobs data raises hopes for Fed easing, putting health care and select retail ETFs and stocks in focus.
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report) shares gapped up prior to trading on Monday following a better than expected earnings announcement. The stock had previously closed at $15.53, but opened at $16.46. Surgery Partners shares last traded at $15.9050, with a volume of 173,693 shares. The company reported $0.10 earnings per share (EPS)
Benchmark SGRY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Surgery Partners, Inc. (SGRY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.56 | $1.9B | -23.87 | 6.24% | -2.35% | -2.18% | — | |
| $82.65 | $1.26B | 58.20 | 16.33% | 0.32% | 0.29% | — | |
| $16.51 | $2.05B | 13.99 | 5.12% | 2.42% | 6.55% | — | |
| $24.37 | $455.81M | 9.87 | 2.63% | 14% | 18.37% | — | |
| $225.01 | $3.51B | 29.34 | 16.94% | 9% | 12.88% | — | |
| $114.93 | $2.15B | 22.06 | 23.21% | 7.13% | 9.57% | — |
Surgery Partners, Inc. (SGRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Surgery Partners, Inc. (SGRY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Jul 24, 2026·SEC
Jun 5, 2026·SEC
Get notified when SGRY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Surgery Partners, Inc. (SGRY) stock FAQ — growth, dividends, profitability & financials explained
Surgery Partners, Inc. (SGRY) reported $3.37B in revenue for fiscal year 2025. This represents a 1083% increase from $284.6M in 2013.
Surgery Partners, Inc. (SGRY) grew revenue by 6.2% over the past year. This is steady growth.
Surgery Partners, Inc. (SGRY) reported a net loss of $88.6M for fiscal year 2025.
Surgery Partners, Inc. (SGRY) has a return on equity (ROE) of -2.2%. Negative ROE indicates the company is unprofitable.
Surgery Partners, Inc. (SGRY) generated $187.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
